Scroll

salicylic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
analgesic anti-inflammatory	2416	69-72-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: choline salicylate choline subsalicylate salicylic acid 2-Carboxyphenol 2-Hydroxybenzenecarboxylic acid 2-Hydroxybenzoic acid imidazole salicylate sodium salicylate morpholine salicylate potassium salicylate	A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions. Molecular weight: 138.12 Formula: C7H6O3 CLOGP: 2.19 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 57.53 ALOGS: -1.09 ROTB: 1

Molecule

Description

Molfile Inchi Smiles

Synonyms:

choline salicylate
choline subsalicylate
salicylic acid
2-Carboxyphenol
2-Hydroxybenzenecarboxylic acid
2-Hydroxybenzoic acid
imidazole salicylate
sodium salicylate
morpholine salicylate
potassium salicylate

A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions.

Molecular weight: 138.12
Formula: C7H6O3
CLOGP: 2.19
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 57.53
ALOGS: -1.09
ROTB: 1

Drug dosage:

Dose	Unit	Route
3	g	O
3	g	O
7	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.51 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	15 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1898	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	399.12	18.53	197	4127	133636	56154107
Toxicity to various agents	185.02	18.53	146	4178	224418	56063325
Skin burning sensation	134.83	18.53	45	4279	10986	56276757
Erythema	116.60	18.53	96	4228	155843	56131900
Acne	103.01	18.53	44	4280	21092	56266651
Skin irritation	93.48	18.53	32	4292	8423	56279320
Dry skin	90.48	18.53	52	4272	47057	56240686
Broncholithiasis	86.67	18.53	15	4309	208	56287535
Skin exfoliation	82.46	18.53	45	4279	36855	56250888
Lymph node calcification	82.28	18.53	15	4309	284	56287459
Drug hypersensitivity	78.85	18.53	101	4223	275104	56012639
Bronchial wall thickening	63.07	18.53	15	4309	1065	56286678
Pain of skin	62.82	18.53	24	4300	8622	56279121
Exposure via ingestion	44.66	18.53	14	4310	2794	56284949
Lichen nitidus	42.28	18.53	7	4317	73	56287670
Suspected suicide	39.08	18.53	15	4309	5451	56282292
Skin swelling	33.54	18.53	11	4313	2535	56285208
Lower respiratory tract infection viral	30.76	18.53	8	4316	819	56286924
Obstructive airways disorder	30.29	18.53	18	4306	17264	56270479
Chemical burn of skin	30.21	18.53	5	4319	52	56287691
Soft tissue necrosis	24.98	18.53	6	4318	444	56287299
Sexual abuse	23.68	18.53	5	4319	206	56287537
Psoriasis	23.28	18.53	32	4292	92660	56195083
Skin hyperpigmentation	22.26	18.53	10	4314	5387	56282356
Nasal congestion	21.48	18.53	24	4300	56346	56231397
Palmoplantar keratoderma	20.44	18.53	4	4320	112	56287631
Therapeutic product effect incomplete	20.00	18.53	32	4292	105999	56181744
Productive cough	19.83	18.53	23	4301	56209	56231534

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	296.25	21.48	153	2894	91361	31602936
Toxicity to various agents	96.76	21.48	102	2945	181385	31512912
Choroiditis	64.00	21.48	16	3031	1116	31693181
Skin burning sensation	63.78	21.48	21	3026	3918	31690379
Acne	53.90	21.48	24	3023	10136	31684161
Endophthalmitis	53.45	21.48	18	3029	3598	31690699
Erythema	44.02	21.48	46	3001	80359	31613938
Dry skin	37.96	21.48	26	3021	25455	31668842
Intraocular pressure increased	36.59	21.48	15	3032	5172	31689125
Uveitis	35.82	21.48	16	3031	6800	31687497
Appendicolith	35.15	21.48	15	3032	5716	31688581
Visual acuity reduced	33.67	21.48	20	3027	15323	31678974
Palmar-plantar erythrodysaesthesia syndrome	30.93	21.48	19	3028	15464	31678833
Appendicitis	30.66	21.48	17	3030	11448	31682849
Chondritis	30.01	21.48	6	3041	149	31694148
Psoriasis	29.68	21.48	29	3018	46690	31647607
Eye pain	29.54	21.48	17	3030	12287	31682010
Condition aggravated	27.26	21.48	53	2994	163956	31530341
Exposure via ingestion	25.71	21.48	9	3038	2016	31692281
Skin exfoliation	23.50	21.48	19	3028	23855	31670442
Suspected suicide	22.73	21.48	10	3037	4097	31690200
Post inflammatory pigmentation change	21.64	21.48	5	3042	249	31694048

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	647.84	18.06	351	6588	226784	70694721
Toxicity to various agents	256.12	18.06	245	6694	381927	70539578
Skin burning sensation	176.36	18.06	59	6880	11367	70910138
Acne	131.51	18.06	59	6880	24930	70896575
Erythema	129.30	18.06	126	6813	199437	70722068
Dry skin	116.76	18.06	71	6868	55860	70865645
Skin irritation	102.48	18.06	38	6901	9871	70911634
Skin exfoliation	92.01	18.06	58	6881	48568	70872937
Broncholithiasis	77.11	18.06	14	6925	200	70921305
Lymph node calcification	69.01	18.06	14	6925	368	70921137
Exposure via ingestion	66.48	18.06	23	6916	4892	70916613
Pain of skin	59.65	18.06	26	6913	10240	70911265
Choroiditis	56.69	18.06	15	6924	1286	70920219
Drug hypersensitivity	54	18.06	94	6845	262365	70659140
Suspected suicide	53.37	18.06	23	6916	8811	70912694
Psoriasis	47.15	18.06	53	6886	98380	70823125
Palmar-plantar erythrodysaesthesia syndrome	44.84	18.06	31	6908	30216	70891289
Bronchial wall thickening	44.81	18.06	14	6925	2165	70919340
Lichen nitidus	40.33	18.06	7	6932	76	70921429
Endophthalmitis	40.15	18.06	17	6922	6238	70915267
Chemical burn of skin	37.64	18.06	7	6932	115	70921390
Appendicolith	35.01	18.06	15	6924	5665	70915840
Soft tissue necrosis	34.07	18.06	9	6930	766	70920739
Skin swelling	32.33	18.06	12	6927	3119	70918386
Appendicitis	26.81	18.06	18	6921	16715	70904790
Intraocular pressure increased	25.77	18.06	14	6925	8887	70912618
Poisoning	24.08	18.06	19	6920	22603	70898902
Chondritis	23.94	18.06	5	6934	152	70921353
Visual acuity reduced	22.57	18.06	20	6919	27910	70893595
Lower respiratory tract infection viral	22.32	18.06	7	6932	1095	70920410
Uveitis	21.49	18.06	15	6924	14830	70906675
Sensitive skin	21.15	18.06	7	6932	1300	70920205
Dermatitis	20.01	18.06	16	6923	19401	70902104
Eye pain	19.17	18.06	20	6919	34082	70887423
Post inflammatory pigmentation change	19.09	18.06	5	6934	412	70921093
Palmoplantar keratoderma	18.72	18.06	5	6934	444	70921061

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D01AE12	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use
ATC	N02BA03	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA04	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA08	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA12	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	N02BA16	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Salicylic acid and derivatives
ATC	S01BC08	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:35718	antifungal agents
CHEBI has role	CHEBI:37848	plant hormones
CHEBI has role	CHEBI:50176	keratolytic drugs
CHEBI has role	CHEBI:73181	ascorbate peroxidase inhibitor
CHEBI has role	CHEBI:76924	plant metabolites
CHEBI has role	CHEBI:84735	algal metabolites
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D007641	Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Pain	indication	22253000
Greasy skin	indication	42273000
Seborrheic dermatitis	indication	50563003	DOID:8741
Allergic rhinitis	indication	61582004
Verruca plantaris	indication	63440008	DOID:13775
Rheumatoid arthritis	indication	69896004	DOID:7148
Common cold	indication	82272006	DOID:10459
Tinea corporis	indication	84849002
Acne vulgaris	indication	88616000
Pityriasis simplex	indication	200767005
Disorder of keratinization	indication	277905003
Fever	indication	386661006
Hyperkeratosis	indication	396228006
Osteoarthritis	indication	396275006
Synovitis	indication	416209007	DOID:2703
Calluses and Corns	indication
Crohn's disease	off-label use	34000006
Tendinitis	off-label use	34840004	DOID:971
Rheumatic fever	off-label use	58718002	DOID:1586
Ulcerative colitis	off-label use	64766004	DOID:8577
Tenosynovitis	off-label use	67801009	DOID:970
Juvenile rheumatoid arthritis	off-label use	410795001
Itching of skin	off-label use	418363000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.81	acidic
pKa2	12.79	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN	Ki	5.15	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN	Ki	5	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN	Ki	4.95	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN	Ki	4.10	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN	Ki	5.06	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN	Ki	4.09	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN	Ki	4.92	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN	Ki	4.30	CHEMBL
High mobility group protein B1	Nuclear other	P09429	HMGB1_HUMAN	Kd	6	CHEMBL
Nicotinate phosphoribosyltransferase	Enzyme	Q6XQN6	PNCB_HUMAN	Ki	9.80	CHEMBL
Salicylic acid-binding protein 2	Enzyme		SABP2_TOBAC			WOMBAT-PK
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE	Ki	4.17	CHEMBL
Polyphenol oxidase 2	Enzyme		PPO2_AGABI	IC50	4	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE	Ki	5.14	CHEMBL
Solute carrier family 22 member 20	Transporter		S22AK_MOUSE	Ki	4.36	CHEMBL

External reference:

ID	Source
4018663	VUID
N0000146974	NUI
D00097	KEGG_DRUG
2016-36-6	SECONDARY_CAS_RN
36364-49-5	SECONDARY_CAS_RN
4018419	VANDF
4018434	VANDF
4018663	VANDF
4018996	VANDF
C0036079	UMLSCUI
CHEBI:16914	CHEBI
SAL	PDB_CHEM_ID
CHEMBL424	ChEMBL_ID
DB00936	DRUGBANK_ID
CHEMBL2104095	ChEMBL_ID
CHEMBL2104788	ChEMBL_ID
CHEMBL447868	ChEMBL_ID
D020156	MESH_DESCRIPTOR_UI
338	PUBCHEM_CID
C015075	MESH_SUPPLEMENTAL_RECORD_UI
4306	IUPHAR_LIGAND_ID
54-21-7	SECONDARY_CAS_RN
147-90-0	SECONDARY_CAS_RN
578-36-9	SECONDARY_CAS_RN
O414PZ4LPZ	UNII
DB14006	DRUGBANK_ID
DB13860	DRUGBANK_ID
20974	RXNORM
4438	MMSL
5235	MMSL
5439	MMSL
5494	MMSL
9170	MMSL
d00492	MMSL
d00843	MMSL
001586	NDDF
001590	NDDF
001592	NDDF
001951	NDDF
005692	NDDF
006027	NDDF
370179008	SNOMEDCT_US
387253001	SNOMEDCT_US
387411000	SNOMEDCT_US
46741005	SNOMEDCT_US
65302009	SNOMEDCT_US
72968006	SNOMEDCT_US
D012980	MESH_DESCRIPTOR_UI
CHEMBL3707214	ChEMBL_ID
CHEMBL3707342	ChEMBL_ID
1938	INN_ID
5485	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SKIN MEDICA Purifying Foaming Wash	HUMAN OTC DRUG LABEL	1	0023-4948	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
Zapzyt Acne Wash Cleanser	HUMAN OTC DRUG LABEL	1	0295-0071	GEL	2 g	TOPICAL	OTC monograph final	9 sections
Zapzyt Acne Wash Cleanser	HUMAN OTC DRUG LABEL	1	0295-9055	GEL	2 g	TOPICAL	OTC monograph final	10 sections
Cetaphil Gentle Clear Mattifying Acne Moisturizer	HUMAN OTC DRUG LABEL	1	0299-4117	LOTION	5 mg	TOPICAL	OTC monograph final	9 sections
Cetaphil Gentle Clear Mattifying Acne Moisturizer	HUMAN OTC DRUG LABEL	1	0299-4117	LOTION	5 mg	TOPICAL	OTC monograph final	9 sections
Cetaphil Gentle Clear Clarifying Acne Cleanser	HUMAN OTC DRUG LABEL	1	0299-4119	CREAM	20 mg	TOPICAL	OTC monograph final	10 sections
Cetaphil Gentle Clear Clarifying Acne Cleanser	HUMAN OTC DRUG LABEL	1	0299-4119	CREAM	20 mg	TOPICAL	OTC monograph final	10 sections
Cetaphil Acne Relief Body Wash	HUMAN OTC DRUG LABEL	1	0299-4121	GEL	20 mg	TOPICAL	OTC monograph final	10 sections
Cetaphil Acne Relief Body Wash	HUMAN OTC DRUG LABEL	1	0299-4121	GEL	20 mg	TOPICAL	OTC monograph final	10 sections
Differin Acne Clearing Body Wash	HUMAN OTC DRUG LABEL	1	0299-4131	GEL	20 mg	TOPICAL	OTC monograph final	11 sections
Differin Acne Clearing Body	HUMAN OTC DRUG LABEL	1	0299-4132	AEROSOL, SPRAY	2 g	TOPICAL	OTC monograph final	11 sections
Cetaphil Gentle Clear Triple-Action Acne Serum	HUMAN OTC DRUG LABEL	1	0299-4135	SOLUTION	5 mg	TOPICAL	OTC monograph final	9 sections
Differin Acne Clearing Body Scrub	HUMAN OTC DRUG LABEL	1	0299-4609	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
Differin Acne Clearing Body Scrub	HUMAN OTC DRUG LABEL	1	0299-4609	LIQUID	20 mg	TOPICAL	OTC monograph final	10 sections
Almay Clear Complexion Liquid Makeup for Oily Skin	HUMAN OTC DRUG LABEL	1	0311-0715	LIQUID	0.50 mg	TOPICAL	OTC monograph final	7 sections
Almay Clear Complexion Blemish Healing Spot Concealer	HUMAN OTC DRUG LABEL	1	0311-0716	LIQUID	2 mg	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Blemish Healing Spot Concealer	HUMAN OTC DRUG LABEL	1	0311-0718	LIQUID	0.01 g	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Liquid Makeup	HUMAN OTC DRUG LABEL	1	0311-0720	LIQUID	2 mg	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Pressed Powder	HUMAN OTC DRUG LABEL	1	0311-0721	POWDER	0.00 g	TOPICAL	OTC monograph final	8 sections
Almay Clear Complexion Blemish Armor	HUMAN OTC DRUG LABEL	1	0311-0722	LIQUID	2 mg	TOPICAL	OTC monograph final	10 sections
ALMAY CLEAR COMPLEXION MAKEUP	HUMAN OTC DRUG LABEL	1	0311-0724	EMULSION	1 mg	TOPICAL	OTC monograph final	7 sections
ALMAY CLEAR COMPLEXION CONCEALER	HUMAN OTC DRUG LABEL	1	0311-0725	LIQUID	2 mg	TOPICAL	OTC monograph final	8 sections
Salicylic acid	HUMAN OTC DRUG LABEL	1	0363-0017	CREAM	5.05 mg	TOPICAL	OTC monograph final	10 sections
Salicylic acid	HUMAN OTC DRUG LABEL	1	0363-0017	CREAM	5.05 mg	TOPICAL	OTC monograph final	10 sections
Charcoal Blackhead Clearing Scrub	HUMAN OTC DRUG LABEL	1	0363-0027	CREAM	20.60 mg	TOPICAL	OTC monograph final	11 sections
Charcoal Blackhead Clearing Scrub	HUMAN OTC DRUG LABEL	1	0363-0027	CREAM	20.60 mg	TOPICAL	OTC monograph final	11 sections
Salicylic Acid	HUMAN OTC DRUG LABEL	1	0363-0203	PATCH	40 mg	TOPICAL	OTC monograph final	12 sections
Salicylic Acid	HUMAN OTC DRUG LABEL	1	0363-0219	GEL	0.17 g	TOPICAL	OTC monograph final	14 sections
Oil-Free Daily Face	HUMAN OTC DRUG LABEL	1	0363-0480	CREAM	2 g	TOPICAL	OTC monograph final	8 sections
Walgreens Oil-Free Acne Wash	HUMAN OTC DRUG LABEL	1	0363-0536	SOLUTION	2 g	TOPICAL	OTC monograph final	9 sections